AIM: This study examines the effect of combining the antiangiogenic effect of αvß₃-targeted fumagillin nanoparticles with the conventional antirheumatic drug methotrexate for the treatment of inflammatory arthritis. METHOD: Arthritis was induced in mice by K/BxN serum transfer, and disease activity was monitored by clinical score and change in ankle thickness. Groups of mice received nanoparticles or methotrexate as single therapy or nanoparticles and methotrexate as combination therapy. RESULTS: We found that animals treated with a pulse dose of fumagillin nanoparticles followed by methotrexate had significantly improved and sustained clinical response compared with those treated with either agent alone. Histological analysis confirmed a significant decrease in inflammatory cell influx, bone erosions, cartilage damage and angiogenesis with the combination therapy. CONCLUSION: Analysis of plasma cytokine levels suggests that fumagillin nanoparticles enhanced the systemic anti-inflammatory effects of methotrexate. Antiangiogenic nanotherapy may represent a promising approach for the treatment of inflammatory arthritis when combined with a conventional antirheumatic drug.
AIM: This study examines the effect of combining the antiangiogenic effect of αvß₃-targeted fumagillin nanoparticles with the conventional antirheumatic drug methotrexate for the treatment of inflammatory arthritis. METHOD:Arthritis was induced in mice by K/BxN serum transfer, and disease activity was monitored by clinical score and change in ankle thickness. Groups of mice received nanoparticles or methotrexate as single therapy or nanoparticles and methotrexate as combination therapy. RESULTS: We found that animals treated with a pulse dose of fumagillin nanoparticles followed by methotrexate had significantly improved and sustained clinical response compared with those treated with either agent alone. Histological analysis confirmed a significant decrease in inflammatory cell influx, bone erosions, cartilage damage and angiogenesis with the combination therapy. CONCLUSION: Analysis of plasma cytokine levels suggests that fumagillin nanoparticles enhanced the systemic anti-inflammatory effects of methotrexate. Antiangiogenic nanotherapy may represent a promising approach for the treatment of inflammatory arthritis when combined with a conventional antirheumatic drug.
Authors: M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann Journal: Clin Exp Immunol Date: 1999-01 Impact factor: 4.330
Authors: Roy S Herbst; Timothy L Madden; Hai T Tran; George R Blumenschein; Christina A Meyers; Lee F Seabrooke; Fadlo R Khuri; Vinay K Puduvalli; Victoria Allgood; Herbert A Fritsche; Leslie Hinton; Robert A Newman; Elizabeth A Crane; Frank V Fossella; Margaret Dordal; Thomas Goodin; Waun Ki Hong Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: Melissa D Howard; Elizabeth D Hood; Blaine Zern; Vladimir V Shuvaev; Tilo Grosser; Vladimir R Muzykantov Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820
Authors: Gregory M Lanza; Chrit Moonen; James R Baker; Esther Chang; Zheng Cheng; Piotr Grodzinski; Katherine Ferrara; Kullervo Hynynen; Gary Kelloff; Yong-Eun Koo Lee; Anil K Patri; David Sept; Jan E Schnitzer; Bradford J Wood; Miqin Zhang; Gang Zheng; Keyvan Farahani Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2013-10-31
Authors: Dipanjan Pan; Nibedita Sanyal; Anne H Schmieder; Angana Senpan; Benjamin Kim; Xiaoxia Yang; Grace Hu; John S Allen; Richard W Gross; Samuel A Wickline; Gregory M Lanza Journal: Nanomedicine (Lond) Date: 2012-06-18 Impact factor: 5.307
Authors: Anne H Schmieder; Patrick M Winter; Todd A Williams; John S Allen; Grace Hu; Huiying Zhang; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza Journal: Radiology Date: 2013-06-14 Impact factor: 11.105